Bioavailability of Ubiquinol in Huntington Disease
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 6
- 试验地点
- 2
- 主要终点
- serum coenzyme Q10 levels
研究概览
简要总结
The death of brain cells in Huntington Disease (HD) is thought to be associated with a lack of normal cell energy and harmful brain substances called free radicals. Coenzyme Q10 (CoQ) is a marketed nutritional supplement that may prove useful in HD because it increases cell energy and combats free radicals.
Most studies of CoQ have looked at only one formulation of CoQ ("ubiquinone") in HD. The purpose of the study is to find out if people that switch from the common formulation of CoQ ("ubiquinone") to a different formulation ("ubiquinol") have higher levels of CoQ in their blood after taking the same dose. The investigators also want to find out if this different formulation is tolerable for individuals with HD.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have manifest Huntington disease
- •Be 18 years of age or older
- •Be taking an oxidized formulation of CoQ for at least 30 days prior to the baseline visit
- •Be on a steady dose of all concomitant medications for at least 30 days prior to the baseline visit
排除标准
- •Have a history of intolerability of sensitivity to CoQ
- •Have an unstable medical or psychiatric illness
- •Be pregnant or breastfeeding; women of childbearing age must use reliable contraception
结局指标
主要结局
serum coenzyme Q10 levels
时间窗: 8 weeks
次要结局
未报告次要终点
研究者
Karl Kieburtz
Professor
University of Rochester